title: High dose cabergoline in management of ovarian hyperstimulation syndrome.
abstract: OBJECTIVE
  To describe a case of moderate ovarian hyperstimulation syndrome (OHSS) that was treated with high dose cabergoline.
  
  
  METHODS
  Case report.
  
  
  METHODS
  Private assisted reproduction center.
  
  
  METHODS
  A 29-year-old woman who developed early moderate OHSS despite preventive cabergoline administration (0.5 mg/day) following controlled ovarian hyperstimulation for IVF treatment.
  
  
  METHODS
  Cabergoline dose was increased to 1 mg/day upon diagnosis of OHSS on the second day after oocyte collection and embryo transfer was postponed to the fifth day after oocyte collection.
  
  
  METHODS
  Resolution of OHSS and achievement of healthy live birth.
  
  
  RESULTS
  OHSS resolved rapidly despite occurrence of pregnancy and patient delivered a healthy boy at term.
  
  
  CONCLUSIONS
  The higher cabergoline dose might have prevented an increase in the severity of OHSS and its prolongation following occurrence of pregnancy. Randomized controlled trials assessing the efficacy and safety of different doses and durations of cabergoline administration in both prophylactic and therapeutic settings are required.
authors.affiliation: American Hospital of Istanbul, Assisted Reproduction Unit, Istanbul, Turkey; Soranus IVF Center, Bursa, Turkey. Electronic address: barisata@hotmail.com.
authors.forename: Baris
authors.initials: B
authors.lastname: Ata
authors.affiliation: American Hospital of Istanbul, Assisted Reproduction Unit, Istanbul, Turkey.
authors.forename: Ayse
authors.initials: A
authors.lastname: Seyhan
authors.affiliation: Soranus IVF Center, Bursa, Turkey.
authors.forename: Serbulent
authors.initials: S
authors.lastname: Orhaner
authors.affiliation: American Hospital of Istanbul, Assisted Reproduction Unit, Istanbul, Turkey.
authors.forename: Bulent
authors.initials: B
authors.lastname: Urman
mesh_terms: D000328:Adult; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000188:drug therapy* / Q000517:prevention & control; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline